Biomarin Pharmaceutical (BSP:B1MR34) EBIT per Share : R$7.78 (TTM As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Biomarin Pharmaceutical EBIT per Share?

Biomarin Pharmaceutical's EBIT per Share for the three months ended in Dec. 2024 was R$2.67. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 was R$7.78.

During the past 12 months, the average EBIT per Share Growth Rate of Biomarin Pharmaceutical was 148.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Biomarin Pharmaceutical's EBIT per Share or its related term are showing as below:

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Biomarin Pharmaceutical was 37.90% per year. The lowest was -53.70% per year. And the median was 9.70% per year.

BSP:B1MR34's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 5.9
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Biomarin Pharmaceutical's EBIT for the three months ended in Dec. 2024 was R$1,049 Mil.

Biomarin Pharmaceutical EBIT per Share Historical Data

The historical data trend for Biomarin Pharmaceutical's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical EBIT per Share Chart

Biomarin Pharmaceutical Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EBIT per Share

Get a 7-Day Free Trial

-0.29

-0.94

2.27

2.59

8.59

Biomarin Pharmaceutical Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EBIT per Share	Get a 7-Day Free Trial															0.29	1.36	1.82	1.93	2.67

Biomarin Pharmaceutical EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Biomarin Pharmaceutical's EBIT per Share for the fiscal year that ended in Dec. 2024 is calculated as

	EBIT per Share		(A: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	3380.576	/	393.416
=	8.59

Biomarin Pharmaceutical's EBIT per Share for the quarter that ended in Dec. 2024 is calculated as

	EBIT per Share		(Q: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	1048.695	/	393.566
=	2.66

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was R$7.78

Biomarin Pharmaceutical (BSP:B1MR34) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Biomarin Pharmaceutical EBIT per Share Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomarin Pharmaceutical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (BSP:B1MR34) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

BMRN:USA BMRN:Mexico 1BMRN:Italy 0HNC:UK BM8:Germany BM8:Germany BMRN:Austria

Address

770 Lindaro Street, San Rafael, CA, USA, 94901

Website

https://www.biomarin.com

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.

Biomarin Pharmaceutical Headlines

No Headlines